Disseminated tumour cells from the bone marrow of early breast cancer patients: Results from an international pooled analysis

2021 ◽  
Vol 154 ◽  
pp. 128-137
Author(s):  
Andreas D. Hartkopf ◽  
Sara Y. Brucker ◽  
Florin-Andrei Taran ◽  
Nadia Harbeck ◽  
Alexandra von Au ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Pooled Analysis ◽  
Tumour Cells ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

scholarly journals Comparison of bone marrow, disseminated tumour cells and blood-circulating tumour cells in breast cancer patients after primary treatment

2008 ◽  
Vol 100 (1) ◽  
pp. 160-166 ◽  
Author(s):  
M J Slade ◽  
R Payne ◽  
S Riethdorf ◽  
B Ward ◽  
S A A Zaidi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Primary Treatment ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

scholarly journals ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients

2008 ◽  
Vol 10 (5) ◽  
Author(s):  
Tanja Fehm ◽  
Natalia Krawczyk ◽  
Erich-Franz Solomayer ◽  
Graziella Becker-Pergola ◽  
Silke Dürr-Störzer ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Primary Breast Cancer ◽  
Tumour Cells ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

Prognostic relevance of disseminated tumour cells from the bone marrow of early stage breast cancer patients – Results from a large single-centre analysis

2014 ◽  
Vol 50 (15) ◽  
pp. 2550-2559 ◽  
Author(s):  
Andreas D. Hartkopf ◽  
Florin-Andrei Taran ◽  
Markus Wallwiener ◽  
Markus Hahn ◽  
Sven Becker ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Early Stage ◽  
Tumour Cells ◽  
Early Stage Breast Cancer ◽  
Breast Cancer Patients ◽  
Single Centre ◽  
Prognostic Relevance ◽  
Disseminated Tumour Cells

The incidence of bone marrow circulating tumour cells in breast cancer patients is directly related to the size of the primary tumour

2003 ◽  
Vol 114 (2) ◽  
pp. 293
Author(s):  
M.A. Kelly ◽  
N. Relihan ◽  
K.C. Redmond ◽  
N.J. Aherne ◽  
J.H. Wang ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Patients ◽  
Primary Tumour ◽  
Tumour Cells ◽  
Circulating Tumour Cells ◽  
Breast Cancer Patients

Detection of breast cancer cells in the bone marrow of early breast cancer patients using quantitative RT PCR for CEA

2005 ◽  
Vol 23 (16_suppl) ◽  
pp. 9638-9638
Author(s):  
F. Janku ◽  
G. Korinkova ◽  
J. Srovnal ◽  
Z. Kleibl ◽  
J. Novotny ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Bone Marrow ◽  
Cancer Cells ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Breast Cancer Cells ◽  
Breast Cancer Patients ◽  
Rt Pcr

1096 Molecular signatures of disseminated tumour cells in metastatic breast cancer patients

2009 ◽  
Vol 7 (2) ◽  
pp. 113-114
Author(s):  
L.O. Baumbusch ◽  
J.B. Geigl ◽  
S. Riethdorf ◽  
I.J. Schneider ◽  
R.M.R. Mathiesen ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Tumour Cells ◽  
Molecular Signatures ◽  
Breast Cancer Patients ◽  
Disseminated Tumour Cells

scholarly journals Spectrum of Epithelial-Mesenchymal Transition Phenotypes in Circulating Tumour Cells from Early Breast Cancer Patients

Cancers ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 59 ◽  
Author(s):  
Aleksandra Markiewicz ◽  
Justyna Topa ◽  
Anna Nagel ◽  
Jaroslaw Skokowski ◽  
Barbara Seroczynska ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Patients ◽  
Early Breast Cancer ◽  
Epithelial Mesenchymal Transition ◽  
Tumour Cells ◽  
Molecular Heterogeneity ◽  
Stem Cell Markers ◽  
Circulating Tumour Cells ◽  
Breast Cancer Patients ◽  
Mesenchymal Transition

Circulating tumour cells (CTCs) can provide valuable prognostic information in a number of epithelial cancers. However, their detection is hampered due to their molecular heterogeneity, which can be induced by the epithelial-mesenchymal transition (EMT) process. Therefore, current knowledge about CTCs from clinical samples is often limited due to an inability to isolate wide spectrum of CTCs phenotypes. In the current work, we aimed at isolation and molecular characterization of CTCs with different EMT status in order to establish their clinical significance in early breast cancer patients. We have obtained CTCs-enriched blood fraction from 83 breast cancer patients in which we have tested the expression of epithelial, mesenchymal and general breast cancer CTCs markers (MGB1/HER2/CK19/CDH1/CDH2/VIM/PLS3), cancer stem cell markers (CD44, NANOG, ALDH1, OCT-4, CD133) and cluster formation gene (plakoglobin). We have shown that in the CTCs-positive patients, epithelial, epithelial-mesenchymal and mesenchymal CTCs markers were detected at a similar rate (in 28%, 24% and 24%, respectively). Mesenchymal CTCs were characterized by the most aggressive phenotype (significantly higher expression of CXCR4, uPAR, CD44, NANOG, p < 0.05 for all), presence of lymph node metastases (p = 0.043), larger tumour size (p = 0.023) and 7.33 higher risk of death in the multivariate analysis (95% CI 1.06–50.41, p = 0.04). Epithelial-mesenchymal subtype, believed to correspond to highly plastic and aggressive state, did not show significant impact on survival. Gene expression profile of samples with epithelial-mesenchymal CTCs group resembled pure epithelial or pure mesenchymal phenotypes, possibly underlining degree of EMT activation in particular patient’s sample. Molecular profiling of CTCs EMT phenotype provides more detailed and clinically informative results, proving the role of EMT in malignant cancer progression in early breast cancer.

Sign in / Sign up

Export Citation Format

Share Document